Cytokine-based immunotherapy of allergic disease.
Human immediate hypersensitivity diseases are strongly associated with an excessive type 2 response to normally innocuous environmental antigens, and are a growing health care concern in developed nations. Commonly prescribed treatments provide effective symptomatic relief, but are unable to consistently ameliorate the underlying cause of allergic disease: the excessive generation of allergen-specific Th2 cells. IL-12 and IL-18 are potent inducers of type 1 immunity, and, as such, have been proposed as candidates for treatment of allergic diseases. This review critically assesses the potential of recombinant IL-12 and IL-18 immunotherapy to redirect both de novo and established allergic responses in animal models of human allergic disease to clinically protective immune responses.
Lewkowich
I P
IP
Department of Immunology, University of Manitoba, Winnipeg, Canada.
HayGlass
K T
KT
D000818:Animals; D016207:Cytokines / Q000627:therapeutic use*; D005786:Gene Expression Regulation; D006801:Humans; D006967:Hypersensitivity / Q000235:genetics / Q000276:immunology / Q000628:therapy*; D006969:Hypersensitivity, Immediate / Q000276:immunology / Q000628:therapy; D007167:Immunotherapy / Q000379:methods*; D018664:Interleukin-12 / Q000096:biosynthesis / Q000235:genetics / Q000627:therapeutic use; D020382:Interleukin-18 / Q000096:biosynthesis / Q000235:genetics / Q000627:therapeutic use; D053727:Interleukin-18 Receptor alpha Subunit; D018448:Models, Immunological; D018123:Receptors, Interleukin / Q000378:metabolism; D053707:Receptors, Interleukin-12; D053724:Receptors, Interleukin-18; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use
D016207:Cytokines; C508572:IL18R1 protein, human; D020382:Interleukin-18; D053727:Interleukin-18 Receptor alpha Subunit; D018123:Receptors, Interleukin; D053707:Receptors, Interleukin-12; D053724:Receptors, Interleukin-18; D011994:Recombinant Proteins; D018664:Interleukin-12